RCKT 8-K: SEC filing

Filed with the SEC on Nov 12, 2026 · accession 0001140361-26-043434

RCKT filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Rocket Pharmaceuticals furnished a press release announcing financial results for the quarter ended September 30, 2026, under Item 2.02 of Form 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantRocket Pharmaceuticals, Inc.

General counsel and chief corporate officerMartin Wilson

✦ Ask GOAX AI about this filing — what it means for RCKT, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for RCKT?

Click here

Frequently asked questions

What did RCKT file with the SEC on Nov 12, 2026?

RCKT filed a 8-K (SEC filing). Rocket Pharmaceuticals furnished a press release announcing financial results for the quarter ended September 30, 2026, under Item 2.02 of Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other RCKT SEC filings

Get alerts when RCKT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

RCKT overview RCKT analysis RCKT news Latest SEC filings